<DOC>
	<DOCNO>NCT01812889</DOCNO>
	<brief_summary>The purpose study determine safety , local tolerability pharmacokinetic parameter TOL-463 intravaginal dosage form healthy , nonpregnant female follow single dose administration ( Part 1 ) , nonpregnant woman vaginitis follow multi-dose administration ( Part 2 ) .</brief_summary>
	<brief_title>Evaluation Intravaginal Gel Ovule Formulations TOL-463</brief_title>
	<detailed_description>The purpose study determine safety , local tolerability pharmacokinetic parameter TOL-463 intravaginal dosage form healthy , nonpregnant female follow single dose administration ( Part 1 ) , nonpregnant woman vaginitis follow multi-dose administration ( Part 2 ) .</detailed_description>
	<criteria>Adult woman race 18 45 year age ( inclusive ) . Subjects must able give voluntary write informed consent study related procedure perform . Subjects must negative serum pregnancy test Screening negative urine pregnancy test clinical site visit , applicable . Subjects either childbearing potential ( define ) ( Note 1 ) agree avoid become pregnant day screen one month last study Day use one follow acceptable method birth control ( Note 2 ) addition use nonlubricated condom male partner ( even vasectomize ) . Hormonal contraceptive Abstinence Note 1 : Nonchildbearing potential define postmenopausal least 2 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy status hysterectomy . Note 2 : Intravaginal intrauterine contraceptive contraceptive device ( IUDs ) acceptable form birth control study . Subjects must agree refrain douche use intravaginal product ( i.e. , contraceptive cream , gel , foam , sponge , lubricant , etc . ) IUDs study period . Subjects must agree donate blood study 14 day end study . Subjects willing able comply study requirement . For Part 1 Only Subjects must healthy determine medical history , physical examination , vital sign , pelvic examination laboratory evaluation ( hematology , clinical chemistry urinalysis test ) within studydefined range Screening . Subjects must without current symptomatic asymptomatic bacterial vaginosis , candida vulvovaginitis form vaginitis clinical microbiologic test . Subjects must willing abstain sexual intercourse 24 hour prior site visit . For Part 2 Only Subjects vaginitis must otherwise healthy base medical history , physical examination , vital sign , pelvic examination laboratory evaluation ( hematology , clinical chemistry urinalysis test ) within studydefined range Screening . Subjects vaginitis must willing abstain sexual intercourse 24 hour prior first dose study medication throughout last visit study . A history clinically significant acute illness ( resolve within 4 week screen ) condition , opinion Site Principal Investigator ( PI ) , would jeopardize safety subject impact validity study result . Subjects intrauterine device . Subjects renal dysfunction ( serum creatinine &gt; /= 1.2 mg/dL ) . Subjects underlying metabolic endocrine dysfunction , diabetes mellitus , Cushing 's disease , Addison 's disease , hypo hyperthyroidism . Subjects test positive HIV , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody . Subjects diseases know cause immunodeficiency , e.g. , AIDS , advance malignancy , anemia severe vitamin deficiency . Subjects test positive Trichomonas vaginalis , Neisseria gonorrhea , Chlamydia trachomatis screen . Subjects active genital lesion screen , include syphilitic chancre , herpetic lesion , genital wart ( HPV ) . Subjects major surgery within 4 week screen . Subjects uncontrolled active illness ( e.g. , active infection ) fever ( oral temperature &gt; /=100 degrees F &gt; /= 37.7 degree C ) screen . Subjects know sensitivity ingredient TOL463 vaginal gel ovule . With exception oral contraceptive , use prescription medication , notably antimicrobial agent , corticosteroid immunosuppressant , within 14 day prior Day 1 study treatment , unless opinion PI , substance would likely impact conduct result study . Subjects current unstable medical condition ( ) require prescription medication ( ) would preclude accurate evaluation subject otherwise impact conduct result study . Subjects receive investigational drug clinical trial within 30 day prior screen . Women pregnant breast feeding . Subject positive history alcohol abuse dependence and/or positive urine screen test alcohol drug abuse [ amphetamine , barbiturate , benzodiazepine , cocaine metabolite , marijuana , opiates , phencyclidine ( PCP ) ] screen checkin prior receive study drug . Subjects donate blood within past 30 day prior Day 1 treatment study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>bacterial vaginosis , vulvovaginal candidiasis , TOL-463 , intravaginal therapy , vaginitis , woman , cross-over</keyword>
</DOC>